Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...
leverages this principle through Proteolysis Targeting Chimera (PROTAC®) technology, which selectively degrades pathological proteins by linking them to E3 ubiquitin ligases. The major advantage of ...
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...
These are molecules — first described in a paper co-authored by Yale University researcher Craig Crews, founder of the first PROTAC-focused drug developer — that exploit naturally-occurring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback